---
document_datetime: 2023-09-21 21:31:55
document_pages: 31
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elaprase-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: elaprase-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 55.491861
conversion_datetime: 2025-12-20 17:40:15.453734
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Elaprase

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3    | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|----------------------------------|-----------|
| IAIN/0108/G          | Thiswas an applicationfor a groupofvariations. A.5.a-Administrative change -Change in the name and/oraddressofamanufacturer/importer responsible for batch release A.1-Administrativechange-Change in thename | 14/12/2022                          |                                            | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII, Labelling,PL(Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | and/oraddressof theMAH                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          |           |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| IB/0107 | B.I.a.2.a-Changes in the manufacturingprocess of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                          | 23/11/2022 | n/a        |          | of the AS |
|         | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/09/2022 | 09/11/2022 | Annex II | S/0099    |
| IB/0106 | B.I.a.4.z-Changetoin-processtestsorlimits appliedduring themanufacture of theAS-Other variation                                                                                                                                                                                                                                                                                                                                                                              | 18/10/2022 | n/a        |          |           |
| I1/0095 | B.I.a.2.c - Changes in the manufacturing process of theAS-The changerefers to a[-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not relatedto aprotocol                                                                                                                                                                                                                          | 22/09/2022 | n/a        |          |           |
|         | Thiswas an applicationfor a group of variations. A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient | 02/09/2022 | n/a        |          | IA/0105/G |

<div style=\"page-break-after: always\"></div>

|           | and/oraddressof amanufactureroranASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient B.I.a.4.z-Change toin-process tests or limits appliedduring themanufactureof theAS-Other variation   |            |            |    |                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------|
| 11/0101   | B.II.g.2-Introduction of a post approvalchange managementprotocolrelatedtothefinishedproduct                                                                                                                                                                             | 01/09/2022 | n/a        |    |                |
| N/0104    | Minor change in labelling or package leaflet not connected with the SPC(Art.61.3Notification)                                                                                                                                                                            | 03/08/2022 | 09/11/2022 | PL |                |
| IB/0102   | B.I.a.2.a -Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS                                                                                                                                                               | 26/07/2022 | n/a        |    |                |
| I1/0098/G | This was an application for a group of variations. PleaserefertotheRecommendationssection                                                                                                                                                                                | 21/07/2022 | n/a        |    | Not applicable |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.b-ChangeintestprocedureforASor startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.II.d.1.f-Change in the specification parameters and/orlimitsofthefinishedproduct-Deletionofa specification parameter which may have a significant effectontheoverallqualityof thefinishedproduct   |            |            |                        |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| IA/0103            | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                  | 19/07/2022 | n/a        |                        |                                |
| IAIN/0100          | B.II.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Notincludingbatchcontrol/testing                                                                                                                                                                                                   | 17/05/2022 | 09/11/2022 | SmPC, Annex II and PL  |                                |
| T/0097             | Transfer ofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                        | 25/02/2022 | 04/04/2022 | SmPC, Labelling and PL |                                |
| IB/0096            | B.I.b.2.e -Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                              | 12/03/2022 | n/a        |                        |                                |
| PSUSA/1722/ 202107 | PeriodicSafetyUpdateEUSingleassessment- idursulfase                                                                                                                                                                                                                                                                                                                                                                      | 10/02/2022 | n/a        |                        | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0093          | A.1-Administrative change-Change in the name and/or addressof theMAH                                                                                                                                                                                                        | 28/07/2021   | 04/04/2022   | SmPC,  Labelling and PL   |                                                                                                                                                                                                                                            |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0092             | Annual re-assessment.                                                                                                                                                                                                                                                       | 22/07/2021   | n/a          |                           |                                                                                                                                                                                                                                            |
| PSUSA/1722/ 202007 | PeriodicSafetyUpdateEUSingle assessment- idursulfase                                                                                                                                                                                                                        | 11/02/2021   | n/a          |                           | PRACRecommendation-maintenance                                                                                                                                                                                                             |
| IA/0091            | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                     | 26/11/2020   | n/a          |                           |                                                                                                                                                                                                                                            |
| S/0087             | 13thannualre-assessment                                                                                                                                                                                                                                                     | 23/07/2020   | n/a          |                           | The CHMP, having reviewed the evidence of compliance withthespecificobligationsandtheimpactofthedata submittedbytheMAHonthebenefit/riskprofileof the medicinalproduct,concludedthatmarketingauthorisation of Elaprase shouldbe maintained. |
| 11/0086            | Updateofsection4.9oftheSmPCinordertoinclude awarningontheriskofanaphylactoidreaction followingoverdosewithElaprase.Thepackageleaflet is updated accordingly. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical,clinical or pharmacovigilance data | 28/05/2020   | 05/11/2020   | SmPC                      | Some patients may experience an anaphylactoid reaction followinganoverdosewithElaprase.                                                                                                                                                    |
| IB/0088/G          | This was an applicationfor a group of variations. B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                          | 11/05/2020   | n/a          |                           |                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                    |            |            |                       |                                |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------|
| IA/0089            | A.5.b-Administrative change-Change in the name and/oraddressofamanufacturer/importerofthe finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease)                                                          | 07/05/2020 | n/a        |                       |                                |
| 11/0082            | B.I.a.2.c-Changes in the manufacturing process of the AS-The change refers to a[-] substance in the manufactureofabiological/immunologicalsubstance whichmay have a significant impact on the medicinal productandisnotrelatedtoaprotocol | 20/02/2020 | n/a        |                       |                                |
| PSUSA/1722/ 201907 | PeriodicSafetyUpdateEUSingle assessment- idursulfase                                                                                                                                                                                      | 13/02/2020 | n/a        |                       | PRACRecommendation-maintenance |
| IB/0084            | C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                      | 14/11/2019 | 05/11/2020 | SmPC, Annex II and PL |                                |
| IAIN/0085          | B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                          | 30/10/2019 | n/a        |                       |                                |
| IB/0081/G          | Thiswasanapplicationforagroupofvariations. B.I.a.1.f-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-                                                                                                   | 17/09/2019 | n/a        |                       |                                |

<div style=\"page-break-after: always\"></div>

|           | Changestoquality controltesting arrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.2.a - Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS B.I.a.4.b-Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b -Change to in-process tests or limits applied during the manufacture of the AS - Addition of anewin-process test andlimits B.I.a.4.c-Change to in-process tests orlimits applied during the manufacture of the AS - Deletion of anon-significant in-process test B.I.a.4.c -Change to in-process tests orlimits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of the AS   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| S/0080    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/07/2019 | n/a |
| IB/0079/G | Thiswas an applicationfor a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/04/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testingtakesplace B.II.d.1.a-Change in the specification parameters and/or limits of thefinishedproduct-Tightening of specification limits B.II.d.1.c-Change in the specification parameters and/orlimitsof thefinishedproduct-Addition of a newspecificationparameter to the specification with its corresponding testmethod   |            |     |                                                                                                                                                                                                                                                                 |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1722/ 201807 | Periodic Safety Update EU Single assessment - idursulfase                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/02/2019 | n/a | PRACRecommendation-maintenance                                                                                                                                                                                                                                  |
| S/0075             | 11thannualre-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/07/2018 | n/a | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationsandtheimpactofthedata submittedbytheMAHonthebenefit/riskprofileofthe medicinal product,concludedthatMarketingAuthorisation underexceptional circumstancesofElapraseshouldbe maintained. |
| I1/0077/G          | Thiswasanapplicationforagroupofvariations. B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.II.d.2.b - Change in test procedure for the finished product-Deletion of a testprocedure if an alternativemethodis already authorised                                                                                            | 21/06/2018 | n/a |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.e-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofa specificationparameterwhichmayhaveasignificant effect on the overall quality of the AS and/or the FP B.I.b.1.z-Change in the specificationparameters and/orlimits of anAS,starting material/intermediate/reagent-Othervariation                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0076   | Updateofsection4.8oftheSmPCtoupdatethe frequency category of the following adverse drug reactions:hypertension,tachypnoea,dyspepsia, erythema and infusion-site swelling, following a reviewof thefrequencies andincidence categories for adverse drug reactions reported with Elaprase, basedonintegrateddatafromallrelevantcompleted studies (i.e. studies TKT024,TKT024EXT and HGT- ELA-038).ThePackageLeaflet isupdated accordingly.In addition,the MarketingAuthorisation Holder(MAH)tookthe opportunity toimplement someminor correctionsto theSmPC. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data | 21/06/2018 | 17/12/2018 | SmPC and PL | Following areviewof thefrequenciesandincidence categoriesfor adverse drugreactionsreportedwith Elaprase,basedonintegrateddatafromallrelevant completed studies(i.e.studiesTKT024,TKT024EXT and HGT-ELA-038),the safety information insection4.8of the SmPCwasupdated.Inthesummaryof safetyprofile,the listofmostcommoninfusion-relatedreactionshasbeen updatedtoinclude'erythema'，'wheezing'，`dyspnoea', 'vomiting',`abdominal pain'，`nausea'and`chestpain'and todeletehypertension'.Thefrequencycategoryfor ‘Hypertension'，'dyspepsia'，'infusionsiteswelling'wasalso amendedfrom'verycommon'to'common',for'erythema' from'common'to'verycommon'andfor'tachypnoea'from `common'to'uncommon'. |
| IA/0074/G | Thiswasanapplicationforagroupofvariations. A.4-Administrative change-Change in the name and/or addressof amanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/03/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                    | intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient A.7-Administrative change-Deletion of manufacturing sites B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product-Deletion of a non-significantin-processtest                                                                                                                                                                                                                                               |            |            |                 |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------|
| PSUSA/1722/ 201707 | PeriodicSafetyUpdateEUSingleassessment- idursulfase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/02/2018 | n/a        |                 | PRACRecommendation-maintenance |
| IAIN/0073          | B.II.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - Notincludingbatchcontrol/testing                                                                                                                                                                                                                                                                                                          | 16/01/2018 | 17/12/2018 | Annex II and PL |                                |
| 11/0071/G          | This was an application for a group of variations. B.I.b.2.d -Change in test procedure for AS or startingmaterial/reagent/intermediate-Substantial change toorreplacementof a biological/immunological/immunochemicaltest methodoramethodusingabiologicalreagentfor a bioloqical AS B.I.b.2.e -Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.1.b.2.e -Change in test procedure forAS or | 07/12/2017 | n/a        |                 |                                |

<div style=\"page-break-after: always\"></div>

|                    | startingmaterial/reagent/intermediate-Other changes to a testprocedure(including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.c - Change in test procedure for the finished product-Substantial change toorreplacementof a biol/immunol/immunochemical test method or a methodusingabiol.reagentorreplacementof a biol. reference preparation not covered by an approved protocol B.II.d.2.d-Change in testprocedure forthe finished product - Other changes to a test procedure (includingreplacement or addition) B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting   |            |     |                                                                                                                                                                                                                                            |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0070             | 10thAnnual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/07/2017 | n/a | The CHMP, having reviewed the evidence of compliance withthespecificobligationsandtheimpactofthedata submittedbytheMAHonthebenefit/riskprofileofthe medicinal product,concludedthatMarketingAuthorisation of Elaprase shouldbe maintained. |
| PSUSA/1722/ 201607 | PeriodicSafetyUpdateEUSingleassessment- idursulfase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/02/2017 | n/a | PRACRecommendation-maintenance                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IB/0069   | B.II.c.3.a.2-Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagentsUSEDinthemanufactureofabiol/immunol ASorinabiol/immunolmedicinalproduct                                                                                                                                                              | 16/01/2017   | n/a        |                                  |                                                                                                                                                                                                                                                                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0068/G | This was an applicationfor a group of variations. A.5.b -Administrative change -Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excluding manufacturerforbatchrelease) A.7-Administrative change-Deletionof manufacturing sites B.I.a.4.z-Change toin-process tests or limits appliedduringthemanufactureoftheAS-Other variation | 18/10/2016   | n/a        |                                  |                                                                                                                                                                                                                                                                |
| R/0065    | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                            | 21/07/2016   | 09/09/2016 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, theCHMPconsidered that thebenefit-riskbalanceof Elaprase inthe approved indicationremainsfavourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0066 | A.1-Administrative change -Change in the name and/or addressof theMAH                                                                                                                                                                                                                                                                                                                             | 22/07/2016   | 09/09/2016 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                |
| S/0064    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                             | 21/07/2016   | n/a        |                                  |                                                                                                                                                                                                                                                                |
| IB/0063   | B.II.f.1.b.5-Stability of FP-Extension of the shelf                                                                                                                                                                                                                                                                                                                                               | 31/03/2016   | 09/09/2016 | SmPC                             |                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                    | life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                    |            |            |             |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| PSUSA/1722/ 201507 | PeriodicSafetyUpdateEUSingle assessment- idursulfase                                                                                                                                                                                                                                                                                                                                                                           | 11/02/2016 | n/a        |             | PRACRecommendation-maintenance |
| IA/0062/G          | This was an applicationfor a group of variations. B.I.b.1.b-Change in the specificationparameters and/or limits of anAS,starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.II1.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished | 22/12/2015 | n/a        |             |                                |
| I1/0058            | Updateofsection6.6oftheSmPCinorder to align withthegeneralphysicians'practices andspecifies thattotalvolume of infusion shouldbe delivered using a 0.2 μm in line filter.Section 4.2 is updated to cross-refer to section 6.6.ThePackageLeafletis updated accordingly. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical,clinical orpharmacovigilance data                                           | 22/10/2015 | 09/09/2016 | SmPC and PL |                                |

<div style=\"page-break-after: always\"></div>

| IAIN/0061   | B.II.b.2.c.1-Change to importer,batch release arrangements andquality control testing of the FP- Replacementoradditionofamanufacturer responsibleforimportationand/orbatchrelease- Not including batch control/testing                                                                                                                                                                         | 16/10/2015   | 09/09/2016   | Annex II and PL   |                                                                                                                                                                                                                                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0621     | C.I.8.a-Introduction ofor changes to a summary of Pharmacovigilancesystem-ChangesinQPPV (including contact details)and/or changesin the PSMFlocation                                                                                                                                                                                                                                           | 16/10/2015   | n/a          |                   |                                                                                                                                                                                                                                                   |
| 11/0057     | B.II.d.1.f-Change in the specification parameters and/orlimitsofthefinishedproduct-Deletion of a specificationparameterwhichmay have a significant effect on the overall quality of the finished product                                                                                                                                                                                       | 06/08/2015   | n/a          |                   |                                                                                                                                                                                                                                                   |
| S/0055      | SthAnnualRe-assessment                                                                                                                                                                                                                                                                                                                                                                         | 23/07/2015   | n/a          |                   | The CHMP, having reviewed the evidence of compliance with thespecificobligations andtheimpactofthedata submittedbytheMAHon thebenefit/riskprofileof the medicinal product, concluded that Marketing Authorisation ofElaprase shouldbe maintained. |
| IB/0056/G   | This was an application for a group of variations. B.1.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition)for theASora starting material/intermediate B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised | 19/06/2015   | n/a          |                   |                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0054            | Updateofsections5.1of theSmPCwithclinical efficacyinformationafterrevisionoftheclinical report for study TKT024EXT \"An open-label extension ofStudyTKT024evaluatinglong-termsafetyand clinical outcomes in patients with Hunter syndrome receivingiduronate-2-sulfataseenzymereplacement therapy. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinicalorpharmacovigilance data                                                 | 26/03/2015   | 14/09/2015   | SmPC        | Introductionofclarificationsofpharmacologicaldatainthe product information for Elaprase after clinical study report reviewforstudyTKT024EXT.                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1722/ 201407 | PeriodicSafetyUpdateEUSingle assessment- idursulfase                                                                                                                                                                                                                                                                                                                                                                                                          | 12/02/2015   | n/a          |             | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| I1/0051            | Updateof sections4.4 and4.8of theSmPCtoreflect outcomesof theongoingsurveillanceofanaphylactic reaction in patients treated with idursulfase.Section 4.3 is also updated regarding the contraindication on hypersensitivity.Section2of thePackageLeaflet is amended accordingly.In addition,minoreditorial changesaremadeintheProductInformation(PI). C.I.4-Change(s)intheSPC,LabellingorPLdue to new quality,preclinical, clinical or pharmacovigilance data | 25/09/2014   | 14/09/2015   | SmPC and PL | Following the outcomes of the ongoing surveillance of anaphylactic reaction in patients treated with idursulfase, theCHMPrecommended theinclusionofthe term \"anaphylactic\" in the existing warning on hypersensitivity reaction.Astatementwas also added thatthesereactions may occur up toseveralyears afterinitiating treatment. Additionalamendmentstosection4.3and4.4werealso agreedtoreflectthefactthatsevereorlife-threatening hypersensitivitytoidursulfaseor anyof theexcipientsisa contraindication, if hypersensitivity is not controllable. |
| IB/0052/G          | This was an applicationfor a group of variations. A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                                                                                                                                                         | 06/08/2014   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites B.I.a.4.a -Change to in-process tests or limits applied during the manufacture of the AS - Tighteningofin-processlimits B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changesto anapprovedtestprocedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits correspondingtestmethod   |            |            |                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------|
| S/0050    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 24/07/2014 | n/a        |                                                                                                                          |
| PSUV/0047 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/02/2014 | 23/04/2014 | Refer toScientific conclusions and grounds recommending thevariationtotermsoftheMarketingAuthorisation(s)'for PSUV/0047. |
| IB/0048   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/12/2013 | n/a        |                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0049   | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                    | 06/12/2013   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0045   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                  | 24/10/2013   | 25/11/2013 | Annex II          |                                                                                                                                                                                                                                                                                                                                                       |
| S/0044    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                      | 25/07/2013   | n/a        |                   | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationsandtheimpactofthedata submittedbytheMAHonthebenefit/riskprofileofthe medicinalproduct,concludedthatMarketingAuthorisation of Elaprase should be varied. TheproductinformationforElaprasewasupdatedtoreflect thelatestEMA/QRDtemplateand therevisedlistofspecific obligations. |
| WS/0291   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.a.1.e-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-The changerelates toabiologicalASorastarting material [-l used inthemanufacture of a biological/immunologicalproduct | 21/02/2013   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                       |
| I1/0040   | Update of sections4.4,4.8 and5.1 of theSmPC in ordertoincludeinformationonapost-hoc immunogenicityanalysisofthedatacollectedfrom the treatment-naivepatients in theTKT024 and TKT024EXT studies. In addition,theMAH tookthe opportunity to correct an address in Annex II.A.                                                                               | 17/01/2013   | 19/09/2013 | SmPC and Annex II | TheMAHhas carried out apost-hoc analysis of immunogenicityresultsofuseofElapraseintreatment- naivepatientswithHuntersyndromewhoreceived0.5 mg/kgintravenousElapraseweeklyenzymereplacement therapy whilst enrolled in studies TKT024 and TKT024EXT. StudiesTKT024andTKT024EXThavebeenpreviously assessedbytheCHMP.Patientswereclassifiedaccording to  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| C.I.4-Variations related to significant modifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilancedata   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  | patientswithHuntersyndromeisconsidered tobe unchanged and still positive.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0036  | Annualre-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/11/2012 | n/a        |                                  | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationssubmittedby theMAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balancefor the product remains favourable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0035 | Update of sections 4.2,4.4,4.8,5.1 and5.2 of the SmPC in order to add information about Elaprase use inchildrenof5yearsofageoryoungerinviewof the results of study HGT-ELA-038. The Package Leafletwas updated accordingly.Annex II.C was updatedtoreflectthatSpecificObligation3hasbeen fulfilled.The Labelling was updated with a minor correction. C.I.4-Variationsrelated to significant modifications of theSPCdue inparticular tonewquality,pre- clinical, clinical or pharmacovigilance data | 15/11/2012 | 19/09/2013 | SmPC, Annex II, Labelling and PL | AtthetimeofapprovaloftheInitialMarketing Authorisation,theMarketingAuthorisationHolder(MAH) committedtoconductseveralSpecificObligations.Specific Obligation3wasacommitmenttoconduct astudyofthe useofElapraseonpatientswithHuntersyndromeandwho are under5years of age:this age grouphadnotbeen addressed in studies submittedforinitial authorisation. Patientsunder5yearsofageareconsidered tohave a moresevereformofHuntersyndrome. TocomplywiththisSpecificObligation,theMAHhas submitted studyHGT-ELA-038,a study of useofweekly infusionof0.5mg/kgElaprasein28patientswithHunter syndrome and who are 16 months to 6.5 years of age. Patientswerefollowedover thecourseof1yearexposure to Elaprase. Results submitted by the MAH suggest that, for patients withHuntersyndromein theagerange16monthsto6.5 years of age as described in study HGT-ELA-038, glycosaminoglycanexcretion,liverindexsizeand spleen sizedecreaseinresponsetoweekly infusion ofidursulfase. Overall,results are similar to those describedforsubjects over5yearsof ageinstudyTKT024,submittedforthe initial MA of Elaprase in2007. |

<div style=\"page-break-after: always\"></div>

| The CHMPwas concerned,however,thatthereis a subpopulation ofpatientswhodevelop antibodies against idursulfase and that these antibodieshaveinvivo activity therebyreducing clinicalefficacybenefit.The MAH has confirmed that the clinical efficacy of Elaprase for patients instudyHGT-ELA-038maybesubdividedaccording to antibody development againstElaprase.Patientswithhigh antibody titre and undetectable idursulfase immediately afterinfusion of the currentproduct display areduced response toElaprase as assessed by urinary output of glycosaminoglycans,liversize and spleensize.TheMAH hasfurtherdemonstratedarelationshipbetweenantibody response andunderlying genotype:patientswith idursulfaseproteindetectableafterinfusionofthecurrent productatweek27hadmostlyeithermissenseor frameshiftgenotypeswhereaspatientswithnodetectable idursulfase protein after infusion of the current product had mostlythecompletedeletion/largerearrangement qenotype. It was not possible, however, to predict individualefficacyresponseonthebasisofgenotype. Overall,thesafetyprofileofsubjectsinstudyHGT-ELA-038 issimilartothatdescribedforsubjects inpreviously reportedstudieswherepatientswithHunter syndrome wereover5yearsofage. Adverseeventswere apparentlymore common insubjects whodevelopedantibodiestoidursulfase. TheMAHhasnowidentified\"vomiting\"asanadditional adverseevent. TheMAHwill carry outpharmacovigilanceactivityforthe importantidentifiedrisk\"immunogenicity\"by means of safetydatamonitoringvia theHunterOutcomeSurvey. ForsubjectswithHuntersyndromewhoareunder6.5   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                          |            |     | yearsofageandwhohavemissenseorframeshift genotypes, the benefit/risk balance may be considered to bepositive and in accordwith the already-described benefit/riskbalanceforpatientswithHuntersyndrome and who are over 5 years of age. AlthoughsubjectswithHuntersyndromewhohavethe complete deletion/large rearrangement genotype may display an apparent reduced clinical efficacy response as assessed by the reductions in urinary output of glycosaminoglycans andchange inliversize andspleen size, it was not possible to predict individual efficacy response on thebasis ofgenotype.Overall,theclinical benefitofexposuretoElapraseinthesub-groupofsubjects withHuntersyndromecausedbythecomplete deletion/large rearrangement genotype is considered to outweigh the clinical risk andso thebenefit/riskbalance in this group is also positive. TheCHMPwasof theopinionthatSpecificObligation3has been fulfilled and agreed to introduce information on the useofElapraseonpatientsundertheageof5yearsinthe product information.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0216 | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                    | 14/09/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0042 | B.II.b.2.a-Change tobatchrelease arrangements andqualitycontrol testingoftheFp-Replacement or addition of a site where batch control/testing takes place | 11/09/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0041 | B.I.a.4.b -Change to in-process tests or limits appliedduring themanufactureof theAS-Addition                                                            | 17/08/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | of anewin-process test andlimits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |          |                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------|
| IA/0038/G | This was an application for a group of variations. B.I.a.4.a-Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a -Change to in-process tests orlimits applied during the manufacture of the AS - Tightening of in-processlimits B.I.a.4.b-Changetoin-processtestsorlimits appliedduring themanufactureof theAS-Addition of anewin-process test andlimits B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changesto an approvedtestprocedure B.I.a.4.c-Change to in-process tests orlimits applied during the manufacture of the AS - Deletion | 19/07/2012 | n/a        |          | of a non-significant in-process test |
|           | Thiswas an applicationfor a groupof variations. A.4-Administrative change-Change in the name and/oraddressof amanufacturerorsupplierofthe AS,startingmaterial,reagentorintermediateused inthemanufactureoftheAS A.5.b-Administrative change-Change in the name and/oraddressofamanufacturerof thefinished product, including quality control sites (excluding manufacturerforbatchrelease)                                                                                                                                                                                                                                                                  | 04/06/2012 | 24/09/2012 | Annex II | IG/0175/G                            |

<div style=\"page-break-after: always\"></div>

| R/0032    | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/07/2011   | 03/10/2011   | SmPC, Annex II, Labelling  and PL   | Baseduponthedatathathavebecomeavailablesincethe granting of the initial Marketing Authorisation, the CHMP considersthatthebenefit-riskbalanceofElapraseremains positive, but considers that its safety profile is to be closely monitored for the following reasons: Additional data is required to further characterise and assesses the long-term effectiveness and safety profile of Elaprase in the treatment of Hunter Syndrome.This includesdataonlong termpulmonaryandcardiovascular morbidity and mortality,long term urinaryGAGexcretion patterns, dosing information, long term antibody levels and information onlonger duration infusions. Therefore，baseduponthesafetyprofileofElaprase,the CHMPconcludedthattheMAHshouldsubmitoneadditional renewal applicationin5years time.Furthermore,since there areremainingSpecificObligations,theCHMPisof the opinion that the Marketing Authorisation should remain underexceptional circumstances.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0033/G | Thiswas an applicationfor a group of variations. Toregister newfacilitiesfor the manufacture and qualitycontrol of thefinishedproduct. B.II.b.1.c-Replacementoradditionofa manufacturing site for the FP - Site where any manufacturingoperation(s)takeplace,exceptbatch release，batchcontrol，andsecondarypackaging,for biological/immunological medicinalproducts. B.II.b.2.a-Change tobatchrelease arrangements andqualitycontrol testingoftheFP-Replacement or addition of a site where batch control/testing | 21/07/2011   | 21/07/2011   |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.2.a-Change tobatch release arrangements andqualitycontrol testingof theFP-Replacement or addition of a site where batch control/testing takesplace B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to batch release arrangements andqualitycontrol testingoftheFP-Replacement or addition of a site where batch control/testing takesplace B.II.b.2.a-Change tobatch release arrangements andqualitycontrol testingoftheFP-Replacement or additionof asitewherebatchcontrol/testing takes place   |            |            | takes place   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------|
| IB/0031 | B.I.d.1.a.4-Stability of AS-Change in the re-test period/storageperiod-Extensionorintroductionofa re-testperiod/storageperiodsupportedbyrealtime data                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/03/2011 | n/a        |               |
| I1/0030 | Changestothemanufactureofthefinishedproduct B.II.b.3.c-Changeinthemanufacturingprocessof the finished product - The product is a biological/immunological medicinalproductandthe change requires an assessment of comparability                                                                                                                                                                                                                                                                                                                                               | 17/02/2011 | 28/02/2011 |               |
| IG/0029 | A.5.b-Administrative change-Change in the name and/oraddressofamanufacturerofthefinished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 02/12/2010 | n/a        |               |

<div style=\"page-break-after: always\"></div>

|         | product,including quality control sites(excluding manufacturerforbatchrelease)                                                                                                                                                                                                   |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0028 | New facility for the manufacture of the drug substance B.I.a.1.e-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS-The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunologicalproduct | 24/06/2010 | 06/07/2010 |                 |                                                                                                                                                                                                                                                                                                                                                                                                                |
| S/0027  | 3rd Annual Re-Assesment                                                                                                                                                                                                                                                          | 24/06/2010 | 29/06/2010 |                 | TheCHMP,havingreviewed theevidence ofcompliance withthespecificobligationssubmittedbytheMAH and havingre-assessedthebenefit/riskprofileofthemedicinal product,concludedthatthebenefit/riskbalanceforthe productremainsfavourable.HowevertheMarketing AuthorisationforElapraseshouldremainunderexceptional circumstancesinviewofthependingSpecificObligations                                                   |
| IA/0029 | B.II.b.2.b.1 - Change to batch release arrangements andqualitycontrol testingof theFp-Notincluding batch control/testing                                                                                                                                                         | 18/06/2010 | n/a        | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                |
| I1/0026 | Updateofsection5.1oftheSummaryofProduct Characteristicstoincludethepotentialuseofthe product at home. UpdateofSummaryofProductCharacteristics                                                                                                                                    | 21/01/2010 | 15/03/2010 | SmPC            | DatafromHunterOutcomeSurveyonsafetyofhome therapywithElaparaseinselectedpatientswhohave toleratedinfusionsintheclinicwellhasbeenprovided.The resultsshowlowincidenceofinfusion-relatedreactionsand no treatment-related serious adverse events. Moreover, hometherapyhasthe advantageofconveniencefor patients and theircarers and thepotential forimproving compliance.ConsideringimportanceoftheseresultsMAH |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                         |            |            |             | submitted a typeIIvariation toupdatesection5.1 of the SPC.However,asperCHMPrequestappropriate informationonhome therapywas included insection 4.2. of SPC.                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024 | Additionalsiteandchangesofresponsibilitiesfor exisitingsitesregardingthemanufactureandQuality Controltesting of thedrugsubstance. Change(s)tothemanufacturingprocessforthe active substance                                                                                                                                             | 17/12/2009 | 20/01/2010 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| I1/0023 | Updatetosections4.6and5.3of theSummaryof Product Characteristics to includenew non-clinical data ona segmentIII study(pre andpost- development)andanutero/lactealexcretion biodistribution study and consequential changesto thePackageLeaflet. Update of Summary of Product Characteristics and Package Leaflet                        | 17/12/2009 | 20/01/2010 | SmPC and PL | Three new non-clinical studies(SHGT-1I1-06-007,SHGT- 1I1-06-008andSHGT-1I1-06-009)weresubmittedinthis variationapplication.Thesestudiesrelatedtothepotential effect of idursulfase on pre- and postnatal development, and exposure of offspring in utero or through lactation due to maternal treatment.These new data indicate that idursulfase is transferred to the foetal circulation in utero when administeredby theintravenousroute topregnant rats.Idursulfase is also excreted in breast milk.                        |
| II/0022 | Update tosections4.8and5.1oftheSummary of ProductCharacteristics to include information on the extensiontrialTXT024EXTandconsequential changestothePackageLeaflet. The MAH has also taken the opportunity to amend thePackageLeaflettoalignitwiththeQRDtemplate version 7.3. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 17/12/2009 | 20/01/2010 | SmPC and PL | StudyTXT024EXT,anextensionofTXT024,arandomised placebo-controlled trial ofidursulfase,wassubmitted in this variation application.Theprimary objective of this extensionstudywastocollectlong-termsafetyandclinical outcomedatainpatientswithHuntersyndromewhowere receiving idursulfase enzyme replacement therapy. Long- termtreatmentwithweeklyinfusionsof0.5mg/kg idursulfasewassafe andwell tolerated.The overall clinical experienceduringtheextensionstudyTXT024EXTwas similartothatreportedduringStudyTKT024andsupports |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                           |            |            |          | the long-term administration of idursulfase.                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0025 | Change to the specifications of the drug substance Quality changes                                                        | 17/12/2009 | 12/01/2010 |          |                                                                                                                                                                                                                                                                                                                                                                            |
| S/0019  | 2ndAnnual Reassessment                                                                                                    | 25/06/2009 | 21/09/2009 | Annex II | TheCHMP,havingreviewed theevidenceofcompliance withthespecificobligationssubmittedbytheMAHand having re-assessed the benefit/risk profile of the medicinal product,concluded thatthebenefit/riskbalanceforthe product remains favourable. However the Marketing AuthorisationforElapraseshouldremain underexceptional circumstancesinviewof thependingSpecificObligations. |
| IA/0021 | IA_05_Change in the name and/or addressof a manufacturerofthefinishedproduct                                              | 07/09/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                            |
| 1/0018  | Changes to thepurificationprocess of the drug substance Change(s)to the manufacturing processfor the activesubstance      | 29/05/2009 | 16/06/2009 |          |                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0020 | IA_07_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite                                                       | 27/05/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                            |
| II/0017 | Changes to the purification process of the drug substance Change(s) to the manufacturing process for the active substance | 23/04/2009 | 05/05/2009 |          |                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| I1/0015   | Changes to the release and shelf life specifications for the drug substance and drug product Change(s)to the testmethod(s)and/or specifications for the active substance                                                                                       | 23/04/2009   | 05/05/2009   |                        |                                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0016   | Additional Quality Control testing facility for the drug substance and drug product. Namechangesoffacilitiesresponsibleforthecontrol of the drug substance and manufacture of the drug product. Change(s) to the manufacturing process for the activesubstance | 19/03/2009   | 25/03/2009   |                        |                                                                                                                                                                                                                                                                                                                                    |
| 11/0013   | UpdateoftheDetailedDescriptionofthe PharmacovigilanceSystem(DDPS). UpdateofDDPS(Pharmacovigilance)                                                                                                                                                             | 18/12/2008   | 04/02/2009   | Annex II and Labelling | WiththisvariationtheMAHsubmittedanupdatedDDPS (version3.0).Afterassessing thedocumentation theCHMP concludedthatthesubmittedDDPScontainedallrequired elements.TheCHMPacceptedanupdateofAnnexIIto include anupdatedwording of thesection\"other conditions\" comprising the version numbers of the current DDPSandRiskManagementPlan. |
| I1/0012   | Additionalstoragefacilityforthecellbanks. Change to the control and specifications for the drug substance(release)anddrugproduct(stability). Change(s)to the testmethod(s)and/or specificationsfor the active substance                                        | 20/11/2008   | 28/11/2008   |                        |                                                                                                                                                                                                                                                                                                                                    |
| IA/0014   | IA_01_Change in the name and/or addressof the marketing authorisationholder                                                                                                                                                                                    | 30/10/2008   | n/a          | SmPC, Labelling and    |                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                           |            |            | PL              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0008  | Annual reassessment.                                                                                                                                                                      | 26/06/2008 | 02/09/2008 | Annex II        | The CHMP having reviewed the evidence of compliance with thespecific obligations submittedby theMarketing AuthorisationHolder andhavingre-assessed the benefit/riskprofileforElaprase,concludesthatthebenefit /riskratiofortheproductremainsunchanged. ThelistofSpecificObligationswasrevisedaccordingtothe conclusions of the CHMPdiscussion. TheCHMPconsideredthattheMarketingAuthorisationfor Elapraseshouldremainunderexceptional circumstancesin view of the pending Specific Obligations. |
| I1/0007 | Change(s) to the test method(s) and/or specificationsfor thefinishedproduct                                                                                                               | 24/04/2008 | 30/04/2008 |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0011 | IA_22_a_Submission of TSEPh.Eur.certificate for exc.-Approved/newmanufacturer                                                                                                             | 11/04/2008 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0010 | IA_22_a_Submission of TSE Ph.Eur.certificate for exc.-Approved/newmanufacturer                                                                                                            | 11/04/2008 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0009 | IA_22_a_Submission of TSE Ph.Eur.certificate for exc.-Approved/newmanufacturer                                                                                                            | 11/04/2008 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0006 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf.responsible forBR-not incl.BC/testing                                                                                               | 26/11/2007 | n/a        | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| I1/0001 | Update of Section 4.2, 4.4 and 4.8 of the SPC and section 2 of the PL to include additional safety informationregardinginfusion-relatedreactions resultingfrompost-approvalexperiencewith | 19/07/2007 | 15/10/2007 | SmPC and PL     | During post-marketing use of Elaprase, two patients experiencedsymptomsandsignssuggestiveoflate- emergent anaphylactoidreactions.                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Elaprase. UpdateofSummaryofProductCharacteristicsand PackageLeaflet   |            |            | Foreachof these2patients,onset ofsymptomsoccurred approximately 24 hours after the Elaprase infusion and recoveryfrom aninitial anaphylactoidreaction to the Elaprase.Bothpatientswerenegativeforanti-idursulfase antibody isotypes IgG, IgA, IgM and IgE, based on analysis ofserumsamplesobtainedpriortotheirsubsequent infusion.For onepatient,thesymptomswere treatedwith inhaled beta-adrenergic antagonists, adrenaline, anti- histamines, and corticosteroids as well as hospitalization, while thesecondpatientrequired corticosteroids only.With appropriate pre-treatment and clinical monitoring prior to andduringsubsequentinfusions,bothpatients continue to receiveweeklyElaprasetreatment. NoanaphylacticreactionstoElaprasehavebeenreported todateandnopatientisknown tohavedevelopedIgE antibodies toElaprase.Given therelative infrequency of sucheventstogetherwithevidence thatinfusion-related adverseevents decline over time,andthefact thatboth patientscontinuetoreceiveweeklyElapraseinfusions，the CHMPbelievedthatElapraseremainsasafeandeffective treatmentforpatientswithHuntersyndrome. However,itwasconsideredappropriatetoupdateSection 4.2(Posology and method of administration),4.4(Speciall warnings andprecautionsforuse)and4.8(Underisable effects)oftheSPCandsection2ofthePLtoinclude   |
|---------|-----------------------------------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0002 | Change to the test procedure and/or specification of a raw material   | 19/07/2007 | 24/07/2007 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |